Pharmaceutical Industries Ltd.
Your browser does not support iframes.
See Teva's sites around the world
Japan & S. Korea
Bosnia & Herzegovina
Want to find out more about Teva's locations and phone numbers?
Visit Teva Worldwide
Board of Directors
2017 Annual Report – Form 10-K
Notice of Annual Meeting of Shareholders 2017 – Proxy Statement
Over the Counter (OTC)
Central Nervous System (CNS)
National Network of Excellence
Positions & Policies
Social Impact Report
Multiple Chronic Conditions
Webcasts and Presentations
Dare to be different
Our Guiding Values
Working at Teva
Dare to be different
Search Teva Jobs
New Therapeutic Entities (NTEs)
Go to Parent
Making Good Medicines Even Better
There are thousands of good medicines that help patients in many ways. But some medicines could be better. They might have unwanted side-effects, burdensome dosing regimens, difficult routes of administration or could even have new uses.
Share on Facebook
Share on LinkedIn
Share on Twitter
Innovation Around Existing Molecules
We believe we can make some medicines even better through a pioneering new approach, which aims to create novel new treatments and treatment modalities, based on existing molecules. We call these potential new medicines New Therapeutic Entities (NTEs).
With the vision of bringing added value to patients, doctors and healthcare systems, Teva has created an industry-leading process that leverages our unique competitive advantage – the integration of our generics and specialty R&D capabilities – in the development of new treatments.
This vision has led to a new reality - the groundbreaking creation of a whole new pharmaceutical model.
What is Innovation Around Existing Molecules?
Innovation around existing molecules is all about developing new specialty medicines (NTEs) based on known and approved chemical molecules. These molecules are reformulated, repurposed or re-engineered to be delivered in a new way to address specific, unmet patient needs.
Teva is doing this in an unprecedented way. We are the first company to specifically focus on creating NTEs on an industrialized scale.
We have built a dedicated team and a specifically-designed process for the generation and assessment of potential NTE concepts. This recently initiated process has already delivered a range of potential new treatment options into various stages of development.
NTEs can benefit patients, clinicians and payors. These new drugs can offer improvements such as better efficacy, increased adherence and improved compliance to treatment. Additionally, they offer the potential for fewer side effects and better quality of life as compared to the original formulation. NTEs may also reduce cost of treatment and financial burden to the healthcare system.
Since NTEs are based on known molecules with proven efficacy, they offer the possibility of getting improved medicines to patients faster. They are also likely to have higher development rate success compared to New Chemical Entities (NCEs).
Our NTE development programs include a range of abuse deterrent (AD) opioids for
and a once every 3 months regimen of an extended-release formulation of risperidone - an important drug used in the management of schizophrenia.